denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
Session: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
Monday, December 9, 2024, 10:30 AM-12:00 PM
Disclosures: Carraway: Jazz: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Stemline: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding; Daiichi: Membership on an entity's Board of Directors or advisory committees.